Gout Drugs

In May 2008, the U.S. development Pegloticase made another assessment optimistic statement of what they have learned in the Phase 3 extension trials and open label. Note that Pegloticase still awaiting approval from medical authorities so I write here about a new gout drug that is still under development.

May was a good month for people suffering from gout. Febuxostat (EU trade / brand Adenuric), the first new drug against the major drug drop in more than 40 years, has been approved for marketing in member countries of the European Union.

HOW PEGLOTICASE

What Pegloticase a very interesting, and above all, a drug drop of hope again, is how it works. All drugs used in gout attempt to cure or alleviate disease by reducing uric acid in the body (UA) levels. They do so either by inhibiting its production or to make it easier to remove.

In the world of natural gout remedies, the elimination of uric acid can be improved by making it more soluble. This is done by drinking lots of water and increasing the body's pH levels of different ways.

Pegloticase answer to the problem excess uric acid level is to remove it by ingeniously converting uric acid into something else, a substance called allantoin. Allantoin is more soluble and excreted as uric acid better. The principle comes from the way most animals do. They do this by converting AU into allantoin, but it is something humans can not do naturally. Hence the formulation of Pegloticase.

SUCCESS trial with patients difficult to treat TASTE

Pegloticase is important because the tests were conducted in patients with gout who have not had success with other drugs gout or who have medical conditions that prohibit the use of them. Thus, it was the fight against the most difficult to treat gout, not easier. Difficult to treat cases represent a significant percentage of the world sick with gout.

He was to have a proper degree of success.

Elimination of the gout in his recent statement the more important point was that developing business group extension trial received Pegloticase every two weeks, there were only four attacks of gout in those who had been administered Pegloticase (8 mg) every fortnight for two months in the following months. And none of this group had an attack of gout after five months of treatment Pegloticase, in months. All were patients who underwent a phase 3 trial.

In other groups of patients, there were reductions in attacks and improvement in the reduction of tophi. Tophi are those shaped knotty, awkward looking, pieces of MSU crystals often developing in the longer term gout.

31% of patients who did not reduce tophi at the end of phase 3 trials have shown a reduction in tophi in the trial extension. It seems that the longer a patient is able to drop to Pegloticase the most successful, it may be, in some cases at least tophi.

Other statements have been encouraging all patients extension trial who had responded to prior therapy and who were both on the school week maintained normal levels of uric acid, (some were new joiners). 70% of those on all four weeks of courses that had responded to prior therapy maintained normal levels of uric acid.

This suggests that the progression of the disease can be contained in difficult to treat cases, and therefore can not cause other medical conditions such as kidney stones, heart disease and hypertension.

ADVERSE

Of course, Pegloticase caused side effects in the trial extension in about 1 in 5 patients. The development corporation said that most were mild, moderate or controllable. But in some cases more serious side effects have been described as including the chest and back pain, muscle cramps, sweating and hot flashes.

Pegloticase i.